Related Experiment Video
Updated: May 23, 2026
11:34
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Quantitative analysis of diagnostic guidelines for HER2-status assessment
Albrecht Stenzinger1, Moritz von Winterfeld, Sebastian Aulmann
1Institute of Pathology and National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Heidelberg, Germany.
The Journal of Molecular Diagnostics : JMD
|April 17, 2012
Summary
Accurate HER2 gene amplification testing is crucial for cancer therapy. Current diagnostic guidelines may cause significant ratio variations, leading to incorrect HER2 status diagnoses and impacting patient treatment decisions.
Area of Science:
- Oncology
- Molecular Pathology
- Biostatistics
Background:
- HER2-targeted therapy for breast and gastric cancers relies on accurate HER2 assessment.
- In situ hybridization (ISH) is used to evaluate HER2 gene amplification, calculating ratios against chromosome 17.
- Existing diagnostic guidelines lack rigorous quantitative assessment for data analysis.
Purpose of the Study:
- To quantitatively assess the impact of sample size, signal distribution, and calculation methods on HER2/chromosome 17 ratios.
- To identify potential statistical variations and their influence on HER2 status diagnosis.
- To provide a basis for refining HER2 diagnostic guidelines.
Main Methods:
- Utilized Monte Carlo simulations to analyze HER2/chromosome 17 ratio dependence on key factors.
- Evaluated the effect of varying numbers of cells (sample size).
- Assessed the influence of different gene/chromosome signal distributions and quotient calculation approaches.
Main Results:
- Current recommendations can lead to HER2/CHR17 ratio variations up to 0.94, potentially causing misdiagnosis.
- Borderline cases may receive different amplification diagnoses based on the calculation method (e.g., Brightfield-silver ISH vs. fluorescence ISH).
- The Food and Drug Administration's ratio threshold of 2.0 is sensitive to these variations.
Conclusions:
- Quantitative analysis reveals significant variability in HER2/chromosome 17 ratios under current guidelines.
- Improved diagnostic guidelines should recommend increased cell evaluation and robust data analysis methods.
- Well-designed data analysis is critical for accurate predictive diagnostics in pathology.
